Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00337285 · ClinicalTrials.gov registry record · Phase 3
An Open-label Study of NRP104 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
A Phase 3 study, sponsored by New River Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 349
- Enrollment target
NCT00337285 is a Phase 3 study that has completed, run by New River Pharmaceuticals. The registered enrollment target is 349 participants.
The verdict
NCT00337285, a Phase 3 study, has completed, sponsored by New River Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 349 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the long-term safety and efficacy of three NRP104 doses of 30 mg, 50 mg, or 70 mg, administered at the same time daily, in the treatment of adults with ADHD.
Interventions
- DRUG Vyvanse (lisdexamfetamine dimesylate), NRP104
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 349 participants |
| Start Date | 2006-07 |
| Est. Completion | 2008-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00337285
The ClinicalTrials.gov registry entry for NCT00337285 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 349 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New River Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vyvanse (lisdexamfetamine dimesylate), NRP104 is the first listed.
NCT00337285 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00337285 about?
NCT00337285 is a clinical study titled "An Open-label Study of NRP104 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)". The purpose of this study is to assess the long-term safety and efficacy of three NRP104 doses of 30 mg, 50 mg, or 70 mg, administered at the same time daily, in the treatment of adults with ADHD.
What is the current status of trial NCT00337285?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 349 participants. The study started on 2006-07. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00337285?
The interventions under investigation include: Vyvanse (lisdexamfetamine dimesylate), NRP104 (DRUG).
Who is sponsoring clinical trial NCT00337285?
This trial is sponsored by New River Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.